Site Loader

The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD). David Singh, Eric D. Bateman, Paul W. Jones. The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease. Eric D. Bateman, David Singh, Paul W. Jones, Alvar. This paper presents results from a phase III study of longer duration (Aclidinium To Treat Airway obstruction In COPD patieNts; ATTAIN), which.

Author: Fenrilabar Arat
Country: Denmark
Language: English (Spanish)
Genre: Spiritual
Published (Last): 24 November 2011
Pages: 344
PDF File Size: 20.13 Mb
ePub File Size: 9.11 Mb
ISBN: 992-6-21326-627-5
Downloads: 11814
Price: Free* [*Free Regsitration Required]
Uploader: Nikodal

Twice-daily aclidinium bromide in COPD patients: Int J Clin Pharmacol Ther. Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Glycopyrronium bromide is a synthetic quaternary ammonium compound, which has been used for many years to reduce secretions and block cardiac vagal reflexes before surgery.

Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.

COPD Efficacy Study | TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder)

While additional studies are needed to evaluate its full clinical potential, aclidinium is an important part of this recent expansion of LAMA therapeutic options, providing clinicians and patients with an effective and well-tolerated COPD treatment. Effect of formoterol alone and in combination with aclidinium on electrocardiograms in dogs.

This showed that aclidinium improved the total score and the component scores breathlessness, chest symptoms, and cough and sputum significantly more than placebo Figure 7.

The BID dosing does not appear to be a disadvantage compared to the QD regimes of tiotropium and glycopyrronium, since it may confer better overnight bronchodilation that may be particularly beneficial for patients with significant night and morning symptoms.

Expert Opin Drug Deliv. aclivinium

This article has been cited by other articles in PMC. Safety and tolerability of aclidinium bromide in patients with COPD: Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Preclinical and pharmacological studies demonstrating low systemic bioavailability and a low propensity to induce cardiac arrhythmias were translated into a favorable tolerability profile in the clinical trial program — the adverse event profile of aclidinium was similar to placebo, with a low incidence of anticholinergic and cardiac adverse events.

  ALEJANDRO MELAMED PORQUE NO PDF

Pharmacologic and pharmacokinetic profile Preclinical studies have shown that aclidinium displays high affinity for all five muscarinic receptors, with kinetic selectivity for M 3 receptors over M 2and a shorter duration of action and a faster onset compared with tiotropium bromide.

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease

J Pharmacol Exp Ther. Well tolerated, no anticholinergic side effects reported, no clinical effect on EKG parameters. Eur Respir JOctober National Center for Biotechnology InformationU. Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease. Efficacy and safety Aclidinium has been extensively evaluated in patients with COPD Table 1 attai — 39 and has also been the subject of a recent Cochrane systematic review.

Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: In the ACCORD COPD I study, 31 night-time and morning COPD symptoms were all significantly reduced among patients treated with aclidinium compared with those who received placebo Figure 5and the impact of breathlessness on early morning activities was also significantly reduced with aclidinium versus placebo Figure 6.

Reduced COPD exacerbations associated with aclidinium bromide versus attsin Three long-acting muscarinic antagonists LAMAs are now available in Europe, providing clinicians and patients with a choice of interventions, which is important in COPD, which is clinically a heterogeneous disease.

There was a problem providing the content you requested

wttain Summary review of regulatory action. Abstract Three long-acting muscarinic antagonists LAMAs are now available in Europe, providing clinicians and patients with a choice of interventions, which is important in COPD, which is clinically a heterogeneous disease.

  INTRODUCCION A LA LOGICA MAURICIO BEUCHOT PDF

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Global Initiative for Chronic Obstructive Lung Disease [webpage on the Internet] Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [updated Jan ] [Accessed November 12, ].

Adverse events reported by seven patients receiving aclidinium, eight receiving placebo, and sttain receiving tiotropium Most common AE was COPD exacerbation three patients all receiving placebo. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: Glycopyrronium bromide Glycopyrronium bromide is a synthetic quaternary ammonium compound, which has been used for many years to reduce secretions and block cardiac vagal reflexes before surgery.

Data reported as least squares mean standard error. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects. Breathlessness, health status, and COPD symptoms with aclidinium Significant improvements were seen in breathlessness, health status, and COPD symptoms in the pivotal trials.

Reproduced with permission of the European Respiratory Society: There were no statistically significant differences between the two aclidinium attaih.

The low systemic bio-availability of aclidinium may be an advantage, but more data are needed, as this is a class of drugs with a generally low side-effect rate. Subsequently, studies investigating higher doses and alternative dosing regimens were conducted, 2930 leading to two Phase III studies: In continuation studies, these improvements were sustained for up to 52 weeks.